Document Detail

High-frequency oscillation versus conventional ventilation following surfactant administration and partial liquid ventilation.
MedLine Citation:
PMID:  9710276     Owner:  NLM     Status:  MEDLINE    
Surfactant followed by partial liquid ventilation (PLV) with perfluorocarbon (PFC; LiquiVent) improves oxygenation, lung compliance, and lung pathology in lung-injured animals receiving conventional ventilation (CV). In this study, we hypothesize that high-frequency oscillation (HFO) and CV will provide equivalent oxygenation in lung-injured animals following surfactant repletion and PLV, once lung volume is optimized. After saline-lavage lung injury during CV, newborn piglets were randomized to either HFO (n = 10) or CV (n = 9). HFO animals were stabilized over 15 min without optimization of lung volume; CV animals continued treatment with time-cycled, pressure-limited, volume-targeted ventilation. All animals then received 100 mg/kg of surfactant (Survanta). Thirty minutes later, all received intratracheal PFC to approximate functional residual capacity. Thirty minutes after PLV began, mean airway pressure (MAP) in both groups was increased to improve oxygenation. MAP was directly adjusted during HFO; PEEP and PIP were adjusted during IMV, maintaining a pressure sufficient to deliver 15 mL/kg tidal volume. Animals were treated for 4 h. The CV group showed improved oxygenation following surfactant administration (OI: 26.79 +/- 1.98 vs. 8.59 +/- 6.29, P < 0.0004), with little further improvement following PFC administration or adjustments in MAP. Oxygenation in HFO-treated animals did not improve following surfactant, but did improve following PFC (0I: 27.78 +/- 6.84 vs. 15.86 +/- 5.53, P < 0.005) and adjustments in MAP (OI: 15.86 +/- 5.53 vs. 8.96 +/- 2.18, P < 0.03). After MAP adjustments, there were no significant intergroup differences in oxygenation. Animals in the CV group required lower MAP than animals in the HFO group to maintain similar oxygenation. We conclude that surfactant repletion followed by PLV improves oxygenation during both CV and HFO. The initial response to administration of surfactant and PFC was different for the conventional and high-frequency oscillation groups, likely reflecting the ventilation strategy used; animals in the CV group responded most to surfactant, whereas animals in the HFO group responded most after PFC instillation. The ultimately similar oxygenation of the two groups once lung volume had been optimized suggests that HFO may be used effectively during administration of, and treatment with, surfactant and perfluorocarbon.
J D Mrozek; D R Bing; P A Meyers; J E Connett; M C Mammel
Related Documents :
21693606 - In vitro models for glaucoma research: effects of hydrostatic pressure.
6896816 - Pulmonary oxygen toxicity: possible role of ammonia in desorbing lung surfactant.
8165076 - Doppler-derived systolic pulmonary artery pressure in acute neonatal respiratory distre...
11125926 - Cerebral hemodynamics after exogenous surfactant administration for respiratory distres...
8576786 - Large artery function and alterations in hypertension.
15755466 - Etiology and management of hypertension in chronic kidney disease.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Pediatric pulmonology     Volume:  26     ISSN:  8755-6863     ISO Abbreviation:  Pediatr. Pulmonol.     Publication Date:  1998 Jul 
Date Detail:
Created Date:  1998-10-08     Completed Date:  1998-10-08     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8510590     Medline TA:  Pediatr Pulmonol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  21-9     Citation Subset:  IM    
Infant Pulmonary Research Center, Children's Health Care, St. Paul, Minnesota, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Animals, Newborn
Biological Products*
Disease Models, Animal
Evaluation Studies as Topic
Fluorocarbons / therapeutic use*
High-Frequency Ventilation*
Pulmonary Surfactants / therapeutic use*
Random Allocation
Respiration, Artificial*
Reg. No./Substance:
0/Biological Products; 0/Fluorocarbons; 0/Pulmonary Surfactants; 108778-82-1/beractant

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Aerosolized albuterol improves airway reactivity in infants with acute respiratory failure from resp...
Next Document:  Effect of atmospheric nitric oxide (NO) on measurements of exhaled NO in asthmatic children.